At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 83 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- Female
- Number of participants
- 168
- Started
- 2025-02-10
- Last checked
- 2025-06
Plain English Summary
What is this study?
- • Testing a new treatment for ovarian cancer
- • Clinical study - 168 participants
- • When patients have suspected or confirmed ovarian cancer standard treatment will involve surgery and chemotherapy
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with ovarian cancer
- • Female only
Where?
- • London - Imperial College NHS Healthcare Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
When patients have suspected or confirmed ovarian cancer standard treatment will involve surgery and chemotherapy. However, as with any treatment, it is challenging to predict treatment response in advance. Before treatment, all patients have a CT scan to describe where the cancer is in order to guide the treatment. There is now a new way to analyse routine scans using advanced computing methods, which may give more information about the ovarian cancer. This is called radiomics which analyses features in scans that are not visible to the naked eye. Our group at Imperial College London has worked on developing radiomic models to better understand ovarian cancer. This study aims to determine whether the information gained from this new approach would help us to tailor patient treatment plans to better meet the patient's individual needs, even more than done already. Furthermore, the aim is to understand how different types of ovarian cancer can correlate with the radiomic findings, which may help develop potential treatments in the future.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: Female only
What the study is looking for
- ✓Written (signed and dated) agreement to take part
- ✓Age 18 years or over
- ✓Suspected or confirmed advanced epithelial ovarian cancer (FIGO stage 3B or more)
- ✓Being considered for active anticancer treatment i.e. primary cytoreductive surgery followed by drug treatment or...
- ✓Evaluable baseline portal venous phase CT scan prior to surgical or medical treatment for ovarian cancer
Who cannot take part
- ✗Known contra-indication to CT with IV contrast (e.g. contrast allergy, kidney failure, inability to lie flat);
- ✗Unable to give agreement to take part;
- ✗Known pregnancy;
- ✗No visible disease \<2cm on portal venous phase baseline CT scan;
- ✗Previous surgery for resection of an adnexal mass;
See the full criteria
Where Is This Study? (1 UK site)
Imperial College NHS Healthcare Trust
London, United Kingdom
How to Get in Touch
Christina Fotopoulou, MD, PhD
Sponsor contactCONTACT